CADTH | Evidence Driven
CADTH | Evidence Driven

mepolizumab

Details

Files
Generic Name:
mepolizumab
Project Status:
Active
Therapeutic Area:
Eosinophilic Granulomatosis with Polyangiitis
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0839-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received19-Dec-23

Files

Proposed Project Scope View PDF

Related Content

Last Updated : January 15, 2024